Media coverage about CVS Health Corporation (NYSE:CVS) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CVS Health Corporation earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the pharmacy operator an impact score of 47.0323334796923 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern’s rankings:

CVS Health Corporation (NYSE CVS) traded down 1.56% on Friday, reaching $77.66. The company had a trading volume of 5,005,371 shares. The firm has a market capitalization of $78.95 billion, a price-to-earnings ratio of 15.47 and a beta of 0.91. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $98.44. The stock’s 50-day moving average price is $78.68 and its 200 day moving average price is $78.94.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.02. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The firm had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.36 billion. During the same period in the prior year, the firm earned $1.32 EPS. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities analysts anticipate that CVS Health Corporation will post $5.88 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, August 3rd. Investors of record on Monday, July 24th were issued a $0.50 dividend. The ex-dividend date was Thursday, July 20th. This represents a $2.00 annualized dividend and a yield of 2.58%. CVS Health Corporation’s dividend payout ratio is currently 39.92%.

CVS has been the subject of several recent analyst reports. Vetr raised CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $87.97 target price for the company in a research note on Wednesday, May 24th. Tigress Financial initiated coverage on CVS Health Corporation in a research note on Thursday, April 27th. They set a “buy” rating for the company. Leerink Swann set a $90.00 target price on CVS Health Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Guggenheim reissued a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Finally, Needham & Company LLC initiated coverage on CVS Health Corporation in a research note on Tuesday, June 27th. They set a “hold” rating for the company. Nine analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $91.24.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/19/cvs-health-corporation-cvs-getting-somewhat-favorable-news-coverage-accern-reports.html.

In related news, CFO David M. Denton sold 230,510 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.00, for a total value of $18,440,800.00. Following the completion of the sale, the chief financial officer now directly owns 176,983 shares in the company, valued at approximately $14,158,640. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Helena Foulkes sold 20,332 shares of the stock in a transaction on Monday, June 19th. The shares were sold at an average price of $76.98, for a total value of $1,565,157.36. Following the completion of the sale, the executive vice president now owns 59,300 shares of the company’s stock, valued at $4,564,914. The disclosure for this sale can be found here. Over the last quarter, insiders sold 273,675 shares of company stock valued at $21,831,647. 0.61% of the stock is owned by insiders.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Insider Buying and Selling by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.